Literature DB >> 21484088

European meeting "P2 receptors: new targets for the treatment of osteoporosis".

Niklas Rye Jørgensen1, Jean-Marie Boeynaems, Francesco Di Virgilio.   

Abstract

Entities:  

Year:  2011        PMID： 21484088      PMCID： PMC3146637          DOI： 10.1007/s11302-011-9223-1

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN： 1573-9538            Impact factor:   3.765


× No keyword cloud information.
  4 in total

Review 1.  Regulation of bone resorption and formation by purines and pyrimidines.

Authors:  Astrid Hoebertz; Timothy R Arnett; Geoffrey Burnstock
Journal:  Trends Pharmacol Sci       Date:  2003-06       Impact factor: 14.819

Review 2.  Purinergic signalling and bone remodelling.

Authors:  Isabel R Orriss; Geoffrey Burnstock; Timothy R Arnett
Journal:  Curr Opin Pharmacol       Date:  2010-02-25       Impact factor: 5.547

3.  Bone phenotypes of P2 receptor knockout mice.

Authors:  Isabel Orriss; Susanne Syberg; Ning Wang; Bernard Robaye; Alison Gartland; Niklas Jorgensen; Tim Arnett; Jean-Marie Boeynaems
Journal:  Front Biosci (Schol Ed)       Date:  2011-06-01

4.  A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion.

Authors:  Patrizia Pellegatti; Simonetta Falzoni; Paolo Pinton; Rosario Rizzuto; Francesco Di Virgilio
Journal:  Mol Biol Cell       Date:  2005-06-08       Impact factor: 4.138
  4 in total
  3 in total

Review 1.  Purinergic signalling in the musculoskeletal system.

Authors:  Geoffrey Burnstock; Timothy R Arnett; Isabel R Orriss
Journal:  Purinergic Signal       Date:  2013-08-14       Impact factor: 3.765

Review 2.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 3.  The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression.

Authors:  Geoffrey Burnstock; Gillian E Knight
Journal:  Purinergic Signal       Date:  2017-11-21       Impact factor: 3.765
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.